Impact of Previous Preterm Birth on 17-Hydroxyprogesterone Caproate Use
Author Information
Author(s): Carla E. Ransom, Jeanette R. Chin, Hilary A. Roeder, Tammy R. Sinclair, R. Phillips Heine, Amy P. Murtha
Primary Institution: Duke University Medical Center
Hypothesis
Does the gestational age of prior preterm delivery influence a woman's receipt of 17-hydroxyprogesterone caproate?
Conclusion
Women with earlier preterm deliveries were more likely to be offered and accept 17-OHP-C.
Supporting Evidence
- 82 out of 104 eligible subjects were offered 17-OHP-C.
- 41.5% of those offered declined the treatment.
- The median gestational age of the most recent preterm delivery was significantly lower among subjects who accepted 17-OHP-C.
Takeaway
If a woman had a preterm baby before, she is more likely to be given a special medicine to help her next baby be born on time.
Methodology
Retrospective cohort study of women eligible for 17-OHP-C identified through medical record review.
Potential Biases
Potential patient reporting bias on gestational age and possible undocumented offers of 17-OHP-C.
Limitations
The study is limited to patients captured via medical record search and does not evaluate the efficacy of 17-OHP-C.
Participant Demographics
Predominantly single, African-American women on Medicaid.
Statistical Information
P-Value
P = .02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website